S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Buy THIS stock before Taiwan is attacked (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Buy THIS stock before Taiwan is attacked (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Buy THIS stock before Taiwan is attacked (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Buy THIS stock before Taiwan is attacked (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Buy THIS stock before Taiwan is attacked (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Buy THIS stock before Taiwan is attacked (Ad)
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ:PRAX

Praxis Precision Medicines - PRAX Stock Forecast, Price & News

$0.90
+0.08 (+9.76%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.80
$0.92
50-Day Range
$0.82
$4.98
52-Week Range
$0.80
$13.33
Volume
1.19 million shs
Average Volume
2.18 million shs
Market Capitalization
$47.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Praxis Precision Medicines MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
1,066.7% Upside
$10.50 Price Target
Short Interest
Bearish
10.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Praxis Precision Medicines in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$72,100 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.60) to ($2.77) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

557th out of 995 stocks

Pharmaceutical Preparations Industry

264th out of 482 stocks


PRAX stock logo

About Praxis Precision Medicines (NASDAQ:PRAX) Stock

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

PRAX Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
H.C. Wainwright Keeps Their Hold Rating on Alkermes (ALKS)
PRAX Praxis Precision Medicines, Inc.
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
See More Headlines
Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

PRAX Company Calendar

Last Earnings
2/07/2023
Today
3/27/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRAX
Fax
N/A
Employees
139
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+1,144.4%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-214,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.62 per share

Miscellaneous

Free Float
46,892,000
Market Cap
$44.21 million
Optionable
Not Optionable
Beta
3.24

Key Executives

  • Mr. Marcio Souza M.B.A.Mr. Marcio Souza M.B.A. (Age 42)
    Pres, CEO & Director
    Comp: $1.24M
  • Ms. Nicole Sweeny (Age 47)
    Chief Commercial Officer
    Comp: $646.44k
  • Dr. Steven Petrou B.Sc. (Hons.)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Mr. Timothy Edwin Kelly (Age 49)
    CFO & Treasurer
  • Lauren Mastrocola
    VP of Fin. & Principal Accounting Officer
  • Dr. Karl Hansen Ph.D.
    Chief Technical Operations Officer
  • Alex Kane
    VP of Investor Relations & Corp. Communications
  • Mr. Alex Nemiroff J.D. (Age 43)
    Gen. Counsel & Sec.
  • Ms. Kelly McCue
    Chief People Officer
  • Ms. Alyssa J. S. Wyant (Age 47)
    Chief Regulatory & Quality Officer













PRAX Stock - Frequently Asked Questions

Should I buy or sell Praxis Precision Medicines stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRAX, but not buy additional shares or sell existing shares.
View PRAX analyst ratings
or view top-rated stocks.

What is Praxis Precision Medicines' stock price forecast for 2023?

5 brokerages have issued 12-month price targets for Praxis Precision Medicines' stock. Their PRAX share price forecasts range from $4.00 to $18.00. On average, they anticipate the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 1,144.4% from the stock's current price.
View analysts price targets for PRAX
or view top-rated stocks among Wall Street analysts.

How have PRAX shares performed in 2023?

Praxis Precision Medicines' stock was trading at $2.38 at the start of the year. Since then, PRAX stock has decreased by 64.5% and is now trading at $0.8438.
View the best growth stocks for 2023 here
.

Are investors shorting Praxis Precision Medicines?

Praxis Precision Medicines saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 4,450,000 shares, an increase of 37.8% from the February 28th total of 3,230,000 shares. Based on an average daily volume of 1,970,000 shares, the days-to-cover ratio is currently 2.3 days. Currently, 10.7% of the company's shares are sold short.
View Praxis Precision Medicines' Short Interest
.

When is Praxis Precision Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our PRAX earnings forecast
.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its quarterly earnings data on Tuesday, February, 7th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by $0.14.

When did Praxis Precision Medicines IPO?

(PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

What is Praxis Precision Medicines' stock symbol?

Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX."

Who are Praxis Precision Medicines' major shareholders?

Praxis Precision Medicines' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (5.45%), Verition Fund Management LLC (3.19%), EcoR1 Capital LLC (3.03%), Bank of America Corp DE (2.89%), Vida Ventures Advisors LLC (3.12%) and Geode Capital Management LLC (1.32%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly.
View institutional ownership trends
.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Praxis Precision Medicines' stock price today?

One share of PRAX stock can currently be purchased for approximately $0.84.

How much money does Praxis Precision Medicines make?

Praxis Precision Medicines (NASDAQ:PRAX) has a market capitalization of $44.21 million. The company earns $-214,030,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

How many employees does Praxis Precision Medicines have?

The company employs 139 workers across the globe.

How can I contact Praxis Precision Medicines?

Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The official website for the company is www.praxismedicines.com. The company can be reached via phone at 617-300-8460 or via email at investors@praxismedicines.com.

This page (NASDAQ:PRAX) was last updated on 3/28/2023 by MarketBeat.com Staff